Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164916 · ClinicalTrials.gov registry record · Phase 2
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT02164916 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 106 participants.
The verdict
NCT02164916, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery. Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or without vemurafenib in treating colorectal cancer.
Interventions
- BIOLOGICAL cetuximab
- DRUG irinotecan hydrochloride
- DRUG vemurafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164916
The ClinicalTrials.gov registry entry for NCT02164916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cetuximab is the first listed.
NCT02164916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164916 about?
NCT02164916 is a clinical study titled "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer". This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery. Irinotec...
What is the current status of trial NCT02164916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2014-11. Estimated completion is 2020-11-19.
What interventions are being tested in trial NCT02164916?
The interventions under investigation include: cetuximab (BIOLOGICAL), irinotecan hydrochloride (DRUG), vemurafenib (DRUG).
Who is sponsoring clinical trial NCT02164916?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.